Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For Part 1:~* Age \>=18 years, either sex, any race.~* Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR) criteria.~* Active disease despite DMARD treatment~* Subject must be taking at least one of the allowed DMARDs, and must be able to continue with it during the trial.~* Eligibility for anti tumor necrosis factor (TNF) use according to the following criteria:~  * Participant must have failed conventional treatment according to the investigator's opinion OR local guidelines.~ * Local guidelines regarding safety screening of anti TNF candidates (ie, tuberculosis \[TB\] screening and other safety screening such as vaccination, if applicable) must be met. Chest X-ray and either a PPD skin test or QuantiFERON®-TB Gold test are also required.~ * Anamnesis and physical examination must make the participant eligible for anti TNF use and trial participation according to the investigator's judgment.~For Part 2:~* Participant must have completed Part 1 of this trial.~* Participant must have:~  * good or moderate response to SC golimumab at the end of Month 6 compared to Baseline, AND.~ * no DAS28 ESR remission.~* Both the investigator and the subject must agree to switch the participant's treatment to IV administration as may be required in Part 2 of this trial.~* The investigator must judge that no safety events (eg, serious adverse events \[SAEs\], serious infections, marked injection-site reactions or intolerance to drug) have occurred that could reoccur or aggravate with increased drug exposure.~Exclusion Criteria:~* History of biologic drug use for RA.~* Evidence of active TB. or latent TB that is untreated.~* Moderate to severe heart failure~* Certain inflammatory rheumatic disease other than RA or certain systemic inflammatory condition~* Allergy to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SC-GLM50 (Type: EXPERIMENTAL): In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
- IV GLM 2 mg/kg + GLM50-SC (Type: EXPERIMENTAL): After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
- GLM50-SC (Type: EXPERIMENTAL): After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).